AP231A - Antimalarial composition. - Google Patents
Antimalarial composition. Download PDFInfo
- Publication number
- AP231A AP231A APAP/P/1991/000275A AP9100275A AP231A AP 231 A AP231 A AP 231A AP 9100275 A AP9100275 A AP 9100275A AP 231 A AP231 A AP 231A
- Authority
- AP
- ARIPO
- Prior art keywords
- effective amount
- pharmaceutical composition
- benflumetol
- artemether
- compound
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 239000003430 antimalarial agent Substances 0.000 title abstract description 16
- 230000000078 anti-malarial effect Effects 0.000 title description 13
- DYLGFOYVTXJFJP-MYYYXRDXSA-N lumefantrine Chemical compound C12=CC(Cl)=CC=C2C=2C(C(O)CN(CCCC)CCCC)=CC(Cl)=CC=2\C1=C/C1=CC=C(Cl)C=C1 DYLGFOYVTXJFJP-MYYYXRDXSA-N 0.000 claims abstract description 37
- 229960004985 lumefantrine Drugs 0.000 claims abstract description 36
- 229960000981 artemether Drugs 0.000 claims abstract description 30
- SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 claims abstract description 30
- 201000004792 malaria Diseases 0.000 claims abstract description 29
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical group C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 claims abstract description 16
- 230000002195 synergetic effect Effects 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 16
- 239000002552 dosage form Substances 0.000 claims description 13
- 229960004191 artemisinin Drugs 0.000 claims description 11
- 239000000654 additive Substances 0.000 claims description 8
- -1 cyclohexanecarbonyloxy, benzoyloxy Chemical group 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 229960002970 artemotil Drugs 0.000 claims description 6
- NLYNIRQVMRLPIQ-XQLAAWPRSA-N artemotil Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OCC)O[C@H]4[C@]32OO[C@@]1(C)O4 NLYNIRQVMRLPIQ-XQLAAWPRSA-N 0.000 claims description 6
- 229960002521 artenimol Drugs 0.000 claims description 5
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 claims description 5
- 229960004991 artesunate Drugs 0.000 claims description 5
- BJDCWCLMFKKGEE-CMDXXVQNSA-N chembl252518 Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-CMDXXVQNSA-N 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 4
- 241000282414 Homo sapiens Species 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 13
- 239000003814 drug Substances 0.000 abstract description 13
- 239000007909 solid dosage form Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 22
- 239000002775 capsule Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 206010037660 Pyrexia Diseases 0.000 description 6
- 230000008034 disappearance Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241000224017 Plasmodium berghei Species 0.000 description 4
- 241000223960 Plasmodium falciparum Species 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 3
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010035503 Plasmodium vivax infection Diseases 0.000 description 3
- 201000009976 Plasmodium vivax malaria Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000005469 Vivax Malaria Diseases 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229960003677 chloroquine Drugs 0.000 description 3
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960001962 mefloquine Drugs 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 230000000505 pernicious effect Effects 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- OVCDSSHSILBFBN-UHFFFAOYSA-N Amodiaquine Chemical compound C1=C(O)C(CN(CC)CC)=CC(NC=2C3=CC=C(Cl)C=C3N=CC=2)=C1 OVCDSSHSILBFBN-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000002476 Falciparum Malaria Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 201000011336 Plasmodium falciparum malaria Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 229960001444 amodiaquine Drugs 0.000 description 2
- 229930101531 artemisinin Natural products 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 229930183339 qinghaosu Natural products 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000002511 suppository base Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000011885 synergistic combination Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 208000037972 tropical disease Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000001405 Artemisia annua Nutrition 0.000 description 1
- 240000000011 Artemisia annua Species 0.000 description 1
- 241001481710 Cerambycidae Species 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 1
- 241000223801 Plasmodium knowlesi Species 0.000 description 1
- 208000035999 Recurrence Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229940061229 artemether 20 mg Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 231100000045 chemical toxicity Toxicity 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 229960005179 primaquine Drugs 0.000 description 1
- INDBQLZJXZLFIT-UHFFFAOYSA-N primaquine Chemical compound N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
- 229960000611 pyrimethamine Drugs 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a synergistic composition which comprises the antimalarial agent benflumetol and also antimalarial agent from the artemisinine group such as artemether. The composition can be formulated into solid dosage forms such as tablets and is useful for the treatment of drug resistant malaria useful for the treatment of drug resistant malaria.
Description
The present invention relates to a synergistic antimalarial composition, methods of treating malaria by administering that composition, and to a process for the preparation of that synergistic antimalarial composition.
Drug resistant malaria is a serious clinical and public health problem. The malaria parasite Plasmodium falciparum has developed the versatility of evading the effects of standard drugs such as chloroquine either by genetic mutation or by non-genetic adaption methods.
The spread of Plasmodium falciparum resistant to chloroquine and other antimalarial drugs is a major challenge to health care programms in tropical and subtropical countries. Therefore, novel pharmaceutical compositions which diminish the resistance of malarial parasites, are needed for successful therapy.
The antimalarial effect of compositions containing the individual agent benflumetol has been reported in Chemical Abstracts 97:28538 h and 101:136941u. Other compositions contain combinations of known antimalarial agents. For example, the combination of amodiaquine and tetracycline have been used in the clinic [Suphat Noeypatimanond, et al. ί 1983), Treatment of Plasmodium falciparum malaria with a combination of amodiaquine and tetracycline in central Thailand, Trans. R. Soc. Trop. Med. and Hyg. 73 (3), 338-340], Recently another antimalarial combination FANSIMED (mefloquine, pyrimethamine and sulphadoxine) is undergoing clinical trials [Tropical Diseases Research, Seventh Programme Report, Chapter 2; Malaria, UNDP World Bank/WHO. Published by WHO,
1985].
The use of combinations of artemisinine, its derivatives and other antimalarial compounds, such as quinine, has been proposed in the Indian Patent Application 26 BOM/87 and the German Patent Application P 37 15 378. Also the synergistic effect of a combination of artemisinine and primaquine is known (Wan Yaode, Cang Qizhong, Pharmacy Bulletin,
Vol. 16. No. 1, 1981).
Combinations of the antimalarial agents artemether, arteether, artemisinine, dihydroBAD ORIGINAL
AP000231 artemisinine. or anesunate with quinidine or with mefloquine have been disclosed in the European Patent Application 362 810.
Motivation for the present invention has been drawn from the need in therapy for an improved antimalarial composition of higher activity and lower resistance against malarial parasites such as Plasmodium falciparum.
It has now been found that pharmaceutical compositions containing the active agent benflumetol in combination with the agent artemisinine or especially one of its derivatives such as artemcther have excellent antimalarial activity and are more active than compositions containing only the individual component benflumetol, or alternatively, artemisinine derivatives.
The following invention relates to a pharmaceutical composition suitable for synergistic action of the active components against malaria comprising a synergistically effective amount of a compound of the formula:
combined with a synergistically effective amount of at least one compound of the formula:
wherein R and Rj together represent oxygen or one of R and Rj individually represents hydroxy, C1-C6-alkoxy, Cl-C6-alkenyloxy, CqCj-alkanoyloxy, Carboxy-Cj-C^-alkanoylbad ORIGINAL
- 3 oxy, cyclohexanecarbonyloxy, benzoyloxy or naphthoyloxy and the other represents hydrogen, or a pharmaceutically acceptable salt thereof and optionally pharmaceutically acceptable additives.
The general definitions and terms used in this specification of the invention preferably have the followins meanings:
The term pharmaceutical composition defines a mixture comprising the compound of the formula 1 and at least one compound of the formula II. This mixture either consists of a dry preparation of the active components (1) and t II) such as a lyophilisate or preferably contains additives suitable for the manufacture of a dosage form such as tablets, capsules or suppositories.
The term synergistic action defines the increase of efficacy of the composition above the efficacy level of at least one individual active component at the given dose. Preferably, the efficacy of all active components present in the pharmaceutical composition is increased. The synergistic effect is most desirable as it enables the use of a lower dosage of an individual component and/or improvement of activity above the activity levels of the individual components.
The synergism of the claimed composition is proved by experimental results from in-vitro and in-vivo models. The results show' that the activity of the component according to formula I is raised as compared to the activity of benfiumetol (I) in an individual dosage form and that the activity of the component (II) such as artemether is also being raised.
Synergistic action against malaria of the composition according to the present invention permits the combined application of different drug regimens during therapy by the administration of one dosage form such as one or two tablets per day.
The application of a dosage form comprising the active component benfiumetol (I) allow-s permanent action against malaria. The presence of the second active component (II) in the same dosage form such as artemether (one of R and R[ represents hydrogen and the other represents methoxy) allows immediate and fast action against protozoa after the outbreak of the disease. This is evident from tests carried out in different standard in-vitro and in-vivo pharmacological models.
BAD ORIGINAL ft
AP Ο 0 Ο 2 3 1
- 4 The active component (I), wherein Bu denotes η-butyl, is known under the name benflumetol. see C.A.R.N. 82186-77-4. Pharmaceutical compositions containing benflumetol individually and its activity against malaria are also known, see the abstracts according to C.A. 97:28538h and 101:136941, The preparation of benflumetol has been disclosed in the Published Chinese Patent Application 88/07666.X.
The active component (U) wherein R and Rj together represent oxygen is known under the name artemisinine. The component (Π) wherein one of R and Rj represents hydrogen and the other represents hydroxy is named dihydroartemisinine.
In a compound of the formula II C,-C6-alkoxy preferably represents methoxy or ethoxy. The compound (II) wherein one of R and Rj represents methoxy and the other represents hydrogen is known under the name artemether. The compound (II) wherein one of R and Rj represents ethoxy and the other also represents hydrogen is knowm under the name arteether.
In a compound of the formula II Cj-C6-alkenyloxy is preferably allyloxy. C,-C5-aIkanoyloxy is preferably acetoxy or propionyloxy. Carboxy-C1-C6-alkanoyloxy is preferably carboxy-n-propionyloxy. The carboxy group may be present in salt form (carboxylate), e.g. as sodium or potassium salt The compound (II) wherein one of R and R, represents sodium carboxylate-n-propionyloxy (-O-CO-CH2-CH2-CO2-Na) and the other represents hydrogen is named artesunate.
The active components artemisinine. dihydroartemisinine, arteether and artesunate comprised by formula II are preferred. Especially preferred is artemether.
The generic names used in the specification of the present invention are taken from Tropical Diseases Research, Seventh Programme Report, Chapter 2; Malaria, I'NDP WORLD BANK/WHO. Published by WHO, 1985.
The active components (II) artemisinine, dihydroartemisinine, arteether, artemether and artesunate are known. Artemisinine has been isolated from Artemisia annua L. and subsequently synthesized. It has been used for the treatment of Falciparum malaria [H.P.
Koch (1981) Qinghasosu: a potent antimalarial from plant origin. Pharmacy International (New Drugs), p. 184-185, Elsevier North Holland Biomedical Press; L.J. Bruce-Schwatt (1982), Qinghaosu: a new antimalarial, British Med. J., 184, 767-768]. The clinical
BAD ORIGINAL ft
- 5 evaluation of the activity of artemisinine in 2069 patients was reported by Koch in 1981, of which 1511 patients were treated for a vivax malaria [H.P. Koch (1981) Qinghaosu: a potent antimalarial from plant origin. Pharmacy International (New Drugs), p. 184-185, Elsevier North Holland Biomedical Press], It has also been shown to be active against chloroquine-resistant strains of Plasmodium falciparum in man [J.P. Jiang et al. (1982), Antimalarial activity of mefloquine and qinghasosu. Lancet, ii. 8293, 185-287], Dihydroartemisinine, arteether, artemether, artesunate are semi-synthetic derivatives of artemisinine. Their antimalarial activity is disclosed in different WHO reports. [WHO. Report of the Scientific Working Group on the Chemotherapy Malaria, TDR/Chemal 3rd Review, 85. 3, Geneva, 3-5. June 1985 and the references contained therein].
Conventional pharmaceutically acceptable additives are preferably present in the composition according to the present invention. The additives are used for the preparation of enteral or parenteral dosage forms according to conventional formulation methods.
For oral administration suitable additives include inert diluents or filers, thereby forming dosage forms such as tablets, powders, capsules, and the like. The pharmaceutical compositions can, if desired, contain additional ingredients such as f avourings, binders, excipients and the like.
For example, tablets containing various solid additives such as starch, dextrin, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in soft and hard gelatin capsules, preferred materials therefore include lactose or milk sugar and high molecular weight polyethylene glycols.
For other oral dosage forms the mixture of the compounds can for example be administered in a gelatin capsule. Such formulation could be based on a suitable refined edible oil such as sunflower oil, com oil, peanut oil, coconut oil or til oil.
In a preferred embodiment of the present invention, the active components (I) and (II) are formulated in a single unit dosage form such as tablets or capsules.
The active components (I) and (II) may also be formulated into two individual dosage
BAD ORIGINAL.,
AP Ο Ο Ο 2 3 1
- 6forms contained within one administration system (kit of parts), which are simultaneously or consecutively administered. The same route of administration is possible, e.g. administration of two individual dosage forms contained within one kit of parts. One tablet or capsule containing component (I) and, consecutively, a second dosage form containing component (II) is administered. An individual dose regimen may be developed especially during clinical treatment, e.g. by administering after the first occurrence of malaria a tablet or capsule containing a high dose of the active component (II) or, correspondingly, multiplying lower doses in the beginning of malaria attacks, and administering also a tablet or capsule containing a lower dose of the active component (I). In the course of treatment, dosage forms containing a lower dose of component (II) are administered. Different dosage forms present in one kit-of-parts may also be administered simultaneously or consecutively, e.g. by administration of a tablet containing component (I) and a suppository containing component (II). The dosage range may also be varied according to the dose regimens given above.
The usefulness of the pharmaceutical composition according to the present invention in therapy against malaria is evident from in-vitro and in-vivo results from experiments carried out in established test models. Some results are given in the Examples. The ability of the composition to act as an effective and rapid acting antimalarial agent even against strains of P.berghei known to be extremely resistant against other antimalarial agents reflects the usefulness of the present invention.
The present invention also relates to a method of treatment against malaria which comprises administering to a patient after the outbreak of malaria the above-mentioned pharmaceutical composition comprising the combined active components (I) and (II). The composition is administered to the patient for a period of time of at least four days, preferably five or more days.
The term method of treatment also comprises prophylactic administration of the composition to healthy patients to prevent the outbreak of the disease in high-risk areas of contamination, especially in regions between the tropics of capricorn and cancer.
The dose of the active component benflumetol (I) as contained in the pharmaceutical composition may vary within wide limits and depends on the condition of the patient and the time period elapsed after the outbreak of the disease. Based on in-vivo data from
P.berghei model experiments with mice as reported below in the Examples, it is
f.
BAD ORIGINAL
-Ί established that the daily dose of benflumetol is between about ().2-5.0 mg,/kg, preferably 0.2-10.0 mg/kg and especially about 0.2-5.0 mg/kg. This daily dose can be raised considerably upon need in view of the low toxicity and high tolerability of benflumetol. It is also estimated that the daily dose of component (II) in the composition, especially artemether, is between 0.2 and 5 mg/kg, preferably 0.3-3.0 mg/kg and especially between about 0.4-5.0 mg/kg.
The dose ratio of component (I) to component (II) may also vary within wide limits. It has been determined that synergism will be especially efficient if benflumetol is administered in equal weight amounts or, preferably, in excess amounts as compared to the weight amounts of component (Π) administered. Accordingly, the weight amount of benflumetol may vary from one to ten parts for each part of component (11), especially artemether administered. Preferably, three to seven parts and especially five to six parts of benflumetol are administered for each part of component (II). The dose amounts given and dose ratios refer to daily administrations.
The invention also relates to a process for the preparation of the pharmaceutical composition suitable for synergistic action of the active components against malaria which comprises combining an effective amount of a compound of formula I with an effective amount of a compound of the formula Π and formulating this combination of active components under optional addition of pharmaceutically acceptable additives to a suitable dosage form.
The novel pharmaceutical compositions contain, for example, from 10 % to 80 %, preferably from 20 % to 60 %. of the combination of active components. Pharmaceutical compositions according to the invention are suitable for enteral administration and are, for example, formulated into oral dosage unit forms, such as dragees, tablets, capsules or suppositories. These are manufactured in a manner known per se, for example by means of conventional mixing, granulating, confectioning, dissolving or lyophilising processes. For example, pharmaceutical preparations for oral administration can be obtained by combining the active ingredient with solid carriers, optionally granulating a resulting mixture, and processing the mixture or granulate, if desired or necessary, after the addition of suitable adjuncts, to form tablets or dragde cores.
In a preferred embodiment of the process, the active components (I) and (II) are milled either individually or together to particle sizes from about 10 μ to about 400 μ, preferably
BAD ORIGINAL Ά
AP 0 0 0 2 3 1 μ to 200 μ. At least 90 % of the crystals of the active components are present in these ranees.
Particles of this size are obtained hy conventional comminution methods, e.g. grinding in an air jet mill, ball mill or vibrator mill. Mieronisation is preferably effected by per se by known methods using an ultrasonics disintegrator, e.g. of the Branson Sonifier type as described e.g. in J. Pharm. Sci. 53 (9), 1040-1045 (1965), or by stirring a suspension with a high-speed agitator, for example with a stirrer of the Homorex type (supplied by Brogli & Co., Basel). In these preferred methods, mieronisation is effected at about 500 to 10,000 rpm by dissolving or suspending the combination of active components in an organic solvent, e.g. methanol, ethanol or propylene glycol, and precipitating it in microcrystalline form at ca. 0°-5°C in water or an aqueous salt solution, e.g. 2 % sodium chloride solution which may additionally contain a protective colloid such as gelatin or a cellulose ether, e.g. methyl cellulose or hydroxypropyl methyl cellulose, in low concentration (0.1-1 %), and filtering the resultant stirred suspension. The filter cake is dried at low temperature, e.g. ca. 02-5°C, under vacuum (e.g. below 50 mbar. preferably at 0.5 mbar). The subsequent drying can be effected at ca. 50°-90°C.
The crystals thus obtained are then formulated to granulates, preferably by wet granulation which is carried out according to standard methods.
The pharmaceutical composition is preferably prepared by compressing a granular formulation which is obtained, for example, by sieving and, if desired, by comminuting the drug, with or without the excipients, compacting with another solvent such as ethanol or water, removing the solvent or drying, with or without the addition of lubricants or glidants such as magnesium stearate or TWEEN, comminuting the granules and sieving once more.
The granules can be compressed to tablet cores in a conventional tabletting machine, for example an EKO Korsch eccentric tabletting machine, at a pressure of ca. 10 kN. Coating can be effected by applying an aqueous-ethanolic solution in which, for example, polyethylene glycol and saccharose is dissolved or dispersed.
Dragtie cores are provided with suitable coatings that may be resistant to gastric juices, there being used, inter alia, concentrated sugar solutions that may contain gum arabic, talc, polyvinylpyrrolidone or polyethylene glycol. Colorings or pigments may be added to the
BAD ORIGINAL ft
- 9 tablets or dragtie coalings, for example for identification purposes or to indicate different doses of the active ingredient.
Further orally adminislrable pharmaceutical compositions are dry-filled capsules consisting of gelatin, and also soft sealed capsules consisting of gelatin and plasticiser, such as glycerine or sorbitol. The dry-filled capsules may contain the active components in the form of a granulate, for example in admixture with fillers, such as lactose, binders, such as starches, and/or glidants, such as talc or magnesium stearate, and optionally stabilisers. In soft capsules, the active ingredient is preferably dissolved or suspended in suitable liquids, such as fatty oils, paraffin oil or liquid polyethylene glycols, to which stabilisers may also be added.
Suitable for enteral administration are also suppositories that consist of a combination of the active ingredient and a suppository base. Suitable as suppository bases are, for example, natural or synthetic triglycerides, paraffins, polyethylene glycols or higher alkanols. It is also possible to use gelatin rectal capsules that contain a combination of the active ingredient and a base material; suitable base materials are, for example, liquid triglycerides, polyethylene glycols or paraffin hydrocarbons.
The following Examples illustrate the invention described above; they are not, however, intended to limit the scope of the invention in any way.
Example 1: Determination of dose ratios for the combination of benflumetol with arte me ther:
Albino mice w'ere infected with Plasmodium berghei as test strain. By using orthogonal design, parallel contrast experiments were carried out for different doses of the combination according to the4-day inhibition test method. ED50 or ED^ and the synergistic indices were calculated by means of a linear regression equation.
ED50 or ED^ for individual component
Index of synersism = ED50 or EDgQ for that component in combination
Using this equation, the optimal weight ratio of drugs in this combination against murine malaria is calculated to be 2:0.75 (the index synergism for ED90>6). Based on experiments in murine malaria, experiments in rhesus monkey with Plasmodium Knowlesi
BAD ORIGINAL
AP Ο Ο Ο 2 3 1
- 10were performed and ihe result showed that the optimal weight ratio of drugs in this combination against malaria is 3-6 parts of benflumetol to each part of artemether.
Example 2: The synergism between the components benflumetol and artemether is determined according to the method of Peters: Am. Trop. Med. Parasitol Vol. 62, pg. 488-492 (1968). The results are reported in the following Table:
Blood schizintocidal action of artemether (A) and benflumetol (B) admimistered orally in varying proportions to mice infected with P. Berghei Κ;73 N-strain in 4-day test” according to Peters (Mean values of three experiments)
| Drug and dose (mg/kg/day) | Effective dose of first component (mg/kg/day) | |
| ed50 | ED^q | |
| Benflumetol (B) | 1.30 | 2.70 |
| + A 0.25 | 0.84 | 1.84 |
| + A 0.50 | 0.78 | 1.57 |
| + A 1.00 | 0.51 | 1.16 |
| + A 2.00 | 0.16 | 0.57 |
| -t- A 4.00 | 0.06 | 0.29 |
| Artemether (A) | 2.00 | 5.30 |
| + B 0.37 | 1.49 | 4.46 |
| + B 0.50 | 0.87 | 2.67 |
| + B 0.75 | 0.93 | 3.44 |
| + B 1.00 | 0.37 | 1.21 |
| + B 1.50 | 0.25 | 0.83 |
All points representing ED50 and ED90 of the components A and B present in the combination being located beneath the addition indicate synergism between the individual components.
BAD ORIGINAL $
Example 3: The rate of killing protozoa was determined in-vivo. When the protozoa concentration in the blood of mice increased to high density, a multiple dose equivalent,
i.e. 20x ED9q was given intragastrically. The rate of decrease of protozoae in blood was observed uninterruptedly after administration. The timespan required for 90 % decrease of the protozoae was 49.7 hours for the combination and 64.3 hours for benflumetol alone. Artemether alone could not kill protozoae by more than 90 % before their number increased again.
Example 4: Clinical determination of the best ratio of dose combination between artemether and benflumetol in the combination:
Based on the result of animal experiment with reference to the clinical effective doses of artemether and benflumetol singly, the optimal ratio of dose combination of these two components was calculated to be from 1:4 to 1:6. For example when 1:6 is chosen, the doses of artemether and benflumetol in each tablet would be 20 mg and 120 mg respectively. Two groups of patients given the combination with 1:5 and 1:6 ratios were selected for clinical parallel comparison trials. In both groups, the 3 days and 4 doses treatment scheme was adopted, i.e. 4 tablets were administered at the first time and then 4 tablets each for three more times with 8, 24 and 48 hour intervals. That made altogether 16 tablets for each adult. 40 cases of pernicious malaria were selected and divided randomly into two groups. The following parameters were determined in these two groups after administration: 1) rate for decrease of protozoae at 24 hours; 2) average time for disappearance of protozoae; 3) average time for subsidence of fever; 4) 28-day cure rate.
The results showed that at 24 hours after administration the rates of decrease in protozoa in these two groups were 96.3 % and 94,2 %, the time periods for disappearance of protozoae were 34.8 hours and 36.0 hours and the average time periods for subsidence of fever were 23.2 hours and 22.4 hours respectively. However, the recrudescence rate on the 28th day in the 1:5 group was 20 % as compared to 0 % in the 1:6 group (i.e. all of the patients in this group were cured). These results indicate that the optimum ratio of combination of artemether and benflumetol in the combination for treatment of human malaria is 1:6.
Example 5: Toxicological Evaluation of the artemether-benflumetol combination:
The ratio of combination of 1:6 for artemether and benflumetol was used in these experiments. The medium lethal dose (LD50) for albino mice was found in acute toxicity
BAD ORIGINAL
AP Ο Ο Ο 2 3 1 • ι:
experiments to be 4555 mg/kg for oral administration. Based on grading criteria for chemical toxicity, this complex prescription is of low grade of toxicity. Toxicity experiments for 14 days were performed in rats and beagles, w hich were divided into high-, medium- and low-dose groups. Drugs were administered per os once every' day for successive 14 days. Appetite and body weight were observed, hematological and biological parameters were determined, and pathological examinations were made in major viscera and target organs of the drugs. The results revealed that the basic safety dose in rats was being equivalent from 40-fold to 50-fold of the dose administered to humans. Although some abnormal changes were found in target organs (liver and kidney )in higher dose groups, they recovered to normal on day 28 after administering the last dose. These results indicated that the toxicity of the synergistic combination is low, and the safety range is wide and free from irreversible toxic reactions.
Example 6: Determination of therapeutic effect of individual components as compared to synergistic combination:
Two groups of patients were selected for oral administration and the 3 days and 4 doses treatment scheme. There were 20 patients with pernicious malaria in each group. The therapeutic effect of the combination and artemether and benflumetol singly were compared separately. The doses of both drugs in individual administration were about the same as in the complex prescription. The parameters determined were: 1) the rate for decrease of protozoa at 24 h post administrationem; 2) average time for disappearance of protozoae; 3) average time for fever subsidence; and 4) cure rate at the 28th day.
The rates of decrease in protozoae at 24 hours after administration were found to be 97 %,
95.1 % and 74.5 % for the combination, individual artemether, and individual benflumetol respectively. The times for disappearance of protozoae were 35.6 h. 38.7 h and 68.4 h respectively. The average time for fever subsidence was 23.8 h, 19.7 h and 40 h and the 28-day cure rates were 95 %, 45 % and 65 % respectively. This experimental therapeutic scheme indicated clearly the superiority in therapeutic effect of the combination over the individual drugs.
Example 7: Additional clinical trials for the combination artemether/benflumetol: a) With the 3 days and 4 doses schemes and oral administration, altogether 400 patients with pernicious malaria were treated. Main parametres observed were: 1) average time period for disappearance of protozoae (the results were 23.2 - 41.0); 2) average time period for subsidence of fever (20.4 - 25.7); 3) 28-day cure rate (average 96.8 %).
BAD ORIGINAL ft
- 13 b) The combination composition was also administered with the 3 days and 4 doses treatment scheme, i.e. 4 tablets the first time and then 4 tablets each time at 8. 24 and 48 h with a total of 16 tablets for adults. 48 vivax malaria patients were treated with the combination. The parametres observed were 1) average time for disappearance of protozoa (the results were 22.8 ± 9.5 h) average time for subsidence of fever (13.6 ± 6.9 h); 3) 28-day cure rate (91.67 %). These results demonstrated remarkable therapeutic effect of the combination against vivax malaria.
Example 8: Preparation of Tablets.
| benflumetol | 120 mg |
| artemether | 20 mg |
| corn starch | 100 mg |
| dextrin | 40 mg |
| Tween®-80 | 0,6 mg |
| 15 % paste of com starch | sufficient |
| Mg-stearate | 3 mg |
Artemether crystals are passed trough a 100 mesh size sieve. Benflumetol crystals are passed through a 60 mesh size sieve and mixed with the artemether solid, starch and dextrin. This mixture is passed 3 times through a 40 mesh size sieve. Tween®-80 is added to the paste of starch which is mixed with the above formulation. This mixture is granulated by way of wet-granulation, passed through a 40 mesh size sieve, dried at reduced pressure at 50-60°C. The Mg-stearate is added, and the tablets are pressed.
BAD ORIGINAL
Claims (11)
- Claims1. A pharmaceutical composition suitable for synergistic action of the active components against malaria which comprises a svnergistically effective amount of a compound of the formula:with a svnergistically effective amount of at least one compound of the formula:wherein R and Rj together represent oxygen or one of R and Rj individually represents hydroxy, CrC6-alkoxy, Cj-C0alkenyloxy, C1-C5-alkanoyloxy, Carboxv-CI-C0-alkanoyloxy, cyclohexanecarbonyloxy, benzoyloxy or naphthoyloxy and the other represents hydrogen and a pharmaceutically acceptable salt thereof
- 2. A pharmaceutical composition according to claim 1, which comprises a svnergistically effective amount of benfiumetol (I) combined with a svnergistically effective amount of at least one compound selected from the group consisting of artemisinine, dihydroartemisinine. arteether, artemether and artesunate comprised by formula II.
- 3. A pharmaceutical composition according to claim 1, which comprises a svnergisticallyBAD ORIGINAL- 15 effective amount of benflumetol (1) combined with a synergistieally effective amount of artemether (II).
- 4. A pharmaceutical composition suitable for synergistic action of the active components against malaria which comprises a synergistieally effective amount of benflumetol (I) combined with a synergistieally effective amount of artemether (II).
- 5. A pharmaceutical composition according to claim 1, which comprises one to ten weight amounts of benflumetol (I) combined with one weight amount of a compound of the formula II.
- 6. A pharmaceutical composition according to claim 1, which comprises three to seven weight amounts of benflumetol (I) combined with one weight amount of a compound of the formula II.
- 7. A pharmaceutical composition according to claim 4, which comprises one weight amount of benflumetol (I) combined with five to six weight amounts of artemether (Π).
- 8. A pharmaceutical composition according to claims 5 or 6 , which comprises one weight amount of benflumetol (I) combined with five to six weight amounts of artemether (Π).
- 9. A process for the preparation of a pharmaceutical composition suitable for synergistic action of the active components against malaria which comprises combining a synergistieally effective amount of a compound (I) according to claim 1 with a synergistieally effective amount of at least one compound of the formula (Π) or a pharmaceutically acceptable salt thereof and formulating this combination of active components under optional addition of pharmaceutically acceptable additives to a suitable dosage form.
- 10. A pharmaceutical composition according to claim 1 for use in a method of treating the human or animal body.
- 11. A method of treating malaria which comprises administering to a patient an effective amount of a pharmaeutical composition according to claim 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN90106722A CN1058717A (en) | 1990-08-08 | 1990-08-08 | New antimalarial agent-Coartem and preparation method thereof |
| CN91102575A CN1085527C (en) | 1990-08-08 | 1991-04-24 | Preparation method of synergistic antimalarial compound benzfluorenol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP9100275A0 AP9100275A0 (en) | 1991-07-31 |
| AP231A true AP231A (en) | 1993-01-31 |
Family
ID=25742651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1991/000275A AP231A (en) | 1990-08-08 | 1991-06-12 | Antimalarial composition. |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US5677331A (en) |
| EP (1) | EP0500823B1 (en) |
| JP (1) | JP2562857B2 (en) |
| KR (1) | KR100221689B1 (en) |
| CN (2) | CN1058717A (en) |
| AP (1) | AP231A (en) |
| AT (1) | ATE135209T1 (en) |
| AU (1) | AU642747B2 (en) |
| CA (1) | CA2065285C (en) |
| DE (2) | DE10199038I2 (en) |
| DK (1) | DK0500823T3 (en) |
| EG (1) | EG19905A (en) |
| ES (1) | ES2084168T3 (en) |
| FI (1) | FI921491A0 (en) |
| GR (1) | GR3019313T3 (en) |
| HK (1) | HK1000312A1 (en) |
| HU (1) | HU227345B1 (en) |
| IE (1) | IE72095B1 (en) |
| IL (1) | IL98463A (en) |
| LU (1) | LU90844I2 (en) |
| MA (1) | MA22176A1 (en) |
| NL (1) | NL300048I2 (en) |
| NZ (1) | NZ238477A (en) |
| PT (1) | PT97945B (en) |
| SA (1) | SA91120263B1 (en) |
| WO (1) | WO1992002217A1 (en) |
| ZA (1) | ZA914490B (en) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5637594A (en) * | 1991-04-11 | 1997-06-10 | Ciba Geigy Corporation | Antimalarial synergistic compositions containing benflumetol |
| SG45193A1 (en) * | 1992-02-07 | 1998-01-16 | Ciba Geigy Ag | Antimalarial synergistic compositions containing benflumetol |
| WO1995027964A1 (en) * | 1994-04-12 | 1995-10-19 | Qualcomm Incorporated | Method and apparatus for freight transportation using a satellite navigation system |
| US5657088A (en) * | 1995-12-22 | 1997-08-12 | Cirrus Logic, Inc. | System and method for extracting caption teletext information from a video signal |
| US6136847A (en) * | 1996-12-02 | 2000-10-24 | Johns Hopkins University | Water-soluble trioxanes as potent and safe antimalarial agents |
| CH692321A5 (en) | 1997-11-03 | 2002-05-15 | Mepha Ag | Pharmaceutically effective composition which comprises an effective anti-malarial parasite substance. |
| CO5040050A1 (en) | 1998-06-25 | 2001-05-29 | Novartis Ag | COMPOUNDS OF 2-AMINO-1- (9-ARYLMETYLIDINE-2,7-DICLORO-9H- FLUOREN-4-ILO) -N-SUBSTITUTED TANOLS, PROCEDURES FOR THE OBTAINING AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM. |
| IN191696B (en) | 1999-02-12 | 2003-12-20 | Council Scient Ind Res | |
| EP1267864A1 (en) * | 2000-03-31 | 2003-01-02 | Council Of Scientific & Industrial Research | A synergistic anti-malarial formulation |
| AU2001295979A1 (en) * | 2000-10-20 | 2002-04-29 | Ajinomoto Co., Inc. | Medicinal compositions, dose and method for treating malaria |
| US7842719B2 (en) * | 2002-10-31 | 2010-11-30 | Kemin Foods, L.C. | Use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis C, bovine viral diarrhea and classical swine fever virus |
| WO2004075817A2 (en) * | 2003-02-26 | 2004-09-10 | Vrije Universiteit Brussel | Suspendable pharmaceutical composition |
| BRPI0413767A (en) * | 2003-09-04 | 2006-10-31 | Cipla Ltd | pharmaceutical product or pharmaceutical formulation, process for preparing a pharmaceutical product or pharmaceutical formulation, method for treating a disease and use of at least one artemisinin or a salt, solvate or derivative thereof |
| US20110206636A1 (en) * | 2003-09-16 | 2011-08-25 | Kemin Foods, LLC | Use of Endoperoxides for the Treatment of Infections Caused by Flaviviridae, Including Hepatitis C, Bovine Viral Diarrhea and Classical Swine Fever Virus |
| WO2007017646A2 (en) * | 2005-08-05 | 2007-02-15 | Cipla Limited | Anti-malarial composition comprising artesunate and lumefantrine |
| WO2007036947A1 (en) * | 2005-09-30 | 2007-04-05 | Ipca Laboratories Limited | Delayed release anti-malarial composition |
| EP2034986A2 (en) * | 2006-06-26 | 2009-03-18 | Ranbaxy Laboratories Limited | High dose oral pharmaceutical compositions of artemether and lumefantrine |
| CN100463669C (en) * | 2006-08-31 | 2009-02-25 | 广州市医药工业研究所 | Self-emulsifying agent of compound artemether |
| WO2008098586A1 (en) * | 2007-02-13 | 2008-08-21 | Dafra Pharma N.V. | Pharmaceutical carrier composition and pharmaceutical composition |
| CH700941B1 (en) * | 2007-12-04 | 2010-11-15 | Mepha Ag | A pharmaceutical composition for the treatment of malaria. |
| FR2926993B1 (en) * | 2008-02-06 | 2011-03-11 | Sanofi Aventis | ASSOCIATION BETWEEN A SALT OF BIS-THIAZOLIUM OR ONE OF ITS PRECURSORS AND ARTEMISININ OR ONE OF ITS DERIVATIVES FOR THE TREATMENT OF MALARIA |
| WO2010004573A1 (en) * | 2008-07-07 | 2010-01-14 | Ipca Laboratories Limited | Synergistic antimalarial pharmaceutical composition |
| EA025956B1 (en) * | 2012-03-30 | 2017-02-28 | Зюдцукер Акциенгезелльшафт Маннхайм/Окзенфурт | Compound powder for applying on the surface of a chewing gum core material |
| CN103251584A (en) * | 2013-05-09 | 2013-08-21 | 西安力邦制药有限公司 | Preparation of artemether/benflumetol compound fat emulsion for injection and application of artemether/benflumetol compound fat emulsion in malaria treatment |
| WO2015140709A1 (en) * | 2014-03-19 | 2015-09-24 | Novartis Ag | Solid pharmaceutical dosage forms |
| JP7377717B2 (en) | 2017-04-24 | 2023-11-10 | ノバルティス アーゲー | 2-Amino-L-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-A]pyrazine-7(8H )-il) ethanone and their combination therapeutic regimens |
| CN113599382B (en) * | 2021-08-20 | 2023-01-03 | 兰州大学 | Application of quinoline derivatives in preparation of medicines for treating diabetes and complications thereof |
| CN116410197A (en) * | 2023-03-03 | 2023-07-11 | 五邑大学 | Quinoline ring inner peroxy bridged ring derivative and preparation method thereof |
| CN116747218B (en) * | 2023-08-21 | 2023-10-31 | 山东省中医药研究院 | Patchouli alcohol, Patchouli alcohol compound antimalarial composition and its application in the preparation of anti-malarial drugs |
| LU506390B1 (en) | 2024-02-09 | 2025-08-11 | L2R Sas | Oil-in-water jellified emulsion for use in anti-malarial treatment |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0362810A1 (en) * | 1988-10-07 | 1990-04-11 | Hoechst Aktiengesellschaft | Antimalarial compositions using quinidine, artemisinine and its derivatives |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN85100781B (en) * | 1985-04-01 | 1988-07-06 | 广西壮族自治区桂林制药厂 | Preparation method of artesunate as antimalarial |
| CN85100978A (en) * | 1985-04-01 | 1986-08-13 | 中医研究院中药研究所 | The production technology of dihydroartemisinine |
| CN87101346A (en) * | 1987-06-09 | 1988-03-09 | 山东省中医药研究所 | Extraction technology for artemisia annua element |
| CN1029680C (en) * | 1988-11-10 | 1995-09-06 | 军事医学科学院微生物流行病研究所 | A New Synthetic Process of Luflumetol, a New Antimalarial Drug |
-
1990
- 1990-08-08 CN CN90106722A patent/CN1058717A/en not_active Withdrawn
-
1991
- 1991-04-24 CN CN91102575A patent/CN1085527C/en not_active Expired - Lifetime
- 1991-06-05 DE DE2001199038 patent/DE10199038I2/en active Active
- 1991-06-05 EP EP91911449A patent/EP0500823B1/en not_active Expired - Lifetime
- 1991-06-05 FI FI921491A patent/FI921491A0/en unknown
- 1991-06-05 HU HU9201528A patent/HU227345B1/en unknown
- 1991-06-05 JP JP3510033A patent/JP2562857B2/en not_active Expired - Lifetime
- 1991-06-05 CA CA002065285A patent/CA2065285C/en not_active Expired - Lifetime
- 1991-06-05 ES ES91911449T patent/ES2084168T3/en not_active Expired - Lifetime
- 1991-06-05 WO PCT/EP1991/001033 patent/WO1992002217A1/en active IP Right Grant
- 1991-06-05 AU AU79549/91A patent/AU642747B2/en not_active Expired
- 1991-06-05 DE DE69117922T patent/DE69117922T2/en not_active Expired - Lifetime
- 1991-06-05 AT AT91911449T patent/ATE135209T1/en not_active IP Right Cessation
- 1991-06-05 KR KR1019920700800A patent/KR100221689B1/en not_active Expired - Lifetime
- 1991-06-05 DK DK91911449.6T patent/DK0500823T3/en active
- 1991-06-10 MA MA22451A patent/MA22176A1/en unknown
- 1991-06-11 EG EG35991A patent/EG19905A/en active
- 1991-06-11 NZ NZ238477A patent/NZ238477A/en not_active IP Right Cessation
- 1991-06-12 PT PT97945A patent/PT97945B/en not_active IP Right Cessation
- 1991-06-12 AP APAP/P/1991/000275A patent/AP231A/en active
- 1991-06-12 IL IL9846391A patent/IL98463A/en not_active IP Right Cessation
- 1991-06-12 IE IE198991A patent/IE72095B1/en not_active IP Right Cessation
- 1991-06-12 ZA ZA914490A patent/ZA914490B/en unknown
- 1991-12-10 SA SA91120263A patent/SA91120263B1/en unknown
-
1994
- 1994-03-23 US US08/216,440 patent/US5677331A/en not_active Expired - Lifetime
-
1996
- 1996-03-14 GR GR960400492T patent/GR3019313T3/en unknown
-
1997
- 1997-09-29 HK HK97101870A patent/HK1000312A1/en not_active IP Right Cessation
-
2001
- 2001-07-19 LU LU90844C patent/LU90844I2/en unknown
- 2001-07-19 NL NL300048C patent/NL300048I2/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0362810A1 (en) * | 1988-10-07 | 1990-04-11 | Hoechst Aktiengesellschaft | Antimalarial compositions using quinidine, artemisinine and its derivatives |
Non-Patent Citations (1)
| Title |
|---|
| Parasitology 90, 1985, pp. 705-715, espec. 709-710 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP231A (en) | Antimalarial composition. | |
| HK1000312B (en) | Antimalarial compositions | |
| JPS62240619A (en) | Anticancer | |
| JPH02157223A (en) | Antimalarial drug composition | |
| AU614515B2 (en) | A pharmaceutical combination for the prophylaxis and therapy of malaria | |
| JPH0232093A (en) | Anti-retrovirus difluorinated nucleoside | |
| WO2005023304A2 (en) | Antimalarial compositions and manufacturing process thereof | |
| AU668376B2 (en) | Antimalarial synergistic compositions containing benflumetol | |
| EP0214933A2 (en) | Mixture preparations for the treatment of malaria | |
| US5637594A (en) | Antimalarial synergistic compositions containing benflumetol | |
| EP0583439B1 (en) | Antimalarial synergistic compositions containing benflumetol | |
| US3852454A (en) | Treatment of rheumatoid arthritis | |
| DE69323941T2 (en) | SYNERGISTIC MALARIANS CONTAINING BENFLUMETOL | |
| PL172590B1 (en) | Synergic, benflumethol containing antipaludic agent | |
| JPH0643306B2 (en) | Cancer cell metastasis inhibitor | |
| JPH04230322A (en) | Antimalarial pharmaceutical composition | |
| JP2001503371A (en) | Use of ipriflavone to reduce the number of CD8 + cells | |
| JPH01265025A (en) | Cancer cell metastasis suppressing agent containing n-substituted-1-deoxynojirimycin derivative | |
| JPH01275531A (en) | Suppressant of cancerous cell metastasis |